[go: up one dir, main page]

EP1263453A4 - PHARMACEUTICAL FORMULATION CONSISTING OF A POLYMERMATRIX, FOR REGULATING THE TIME-CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES - Google Patents

PHARMACEUTICAL FORMULATION CONSISTING OF A POLYMERMATRIX, FOR REGULATING THE TIME-CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES

Info

Publication number
EP1263453A4
EP1263453A4 EP01939971A EP01939971A EP1263453A4 EP 1263453 A4 EP1263453 A4 EP 1263453A4 EP 01939971 A EP01939971 A EP 01939971A EP 01939971 A EP01939971 A EP 01939971A EP 1263453 A4 EP1263453 A4 EP 1263453A4
Authority
EP
European Patent Office
Prior art keywords
polymermatrix
regulating
time
biologically active
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01939971A
Other languages
German (de)
French (fr)
Other versions
EP1263453A2 (en
Inventor
Joachim B Kohn
Deborah M Schachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of EP1263453A2 publication Critical patent/EP1263453A2/en
Publication of EP1263453A4 publication Critical patent/EP1263453A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01939971A 1999-12-31 2001-01-02 PHARMACEUTICAL FORMULATION CONSISTING OF A POLYMERMATRIX, FOR REGULATING THE TIME-CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES Ceased EP1263453A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17413799P 1999-12-31 1999-12-31
US174137P 1999-12-31
PCT/US2001/000030 WO2001049249A2 (en) 1999-12-31 2001-01-02 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix

Publications (2)

Publication Number Publication Date
EP1263453A2 EP1263453A2 (en) 2002-12-11
EP1263453A4 true EP1263453A4 (en) 2008-02-20

Family

ID=22634986

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01939971A Ceased EP1263453A4 (en) 1999-12-31 2001-01-02 PHARMACEUTICAL FORMULATION CONSISTING OF A POLYMERMATRIX, FOR REGULATING THE TIME-CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES

Country Status (5)

Country Link
EP (1) EP1263453A4 (en)
JP (1) JP2003519164A (en)
AU (1) AU784226B2 (en)
CA (1) CA2396037A1 (en)
WO (1) WO2001049249A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049311A1 (en) * 1999-12-31 2001-07-12 Rutgers, The State University Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DK1682537T3 (en) 2003-11-05 2012-07-09 Sarcode Bioscience Inc Cell adhesion modulators
EP2444079B1 (en) 2005-05-17 2016-11-30 SARcode Bioscience Inc. Compositions and Methods for Treatment of Eye Disorders
US8636753B2 (en) 2006-02-08 2014-01-28 Tyrx, Inc. Temporarily stiffened mesh prostheses
US8315700B2 (en) 2006-02-08 2012-11-20 Tyrx, Inc. Preventing biofilm formation on implantable medical devices
US9265865B2 (en) 2006-06-30 2016-02-23 Boston Scientific Scimed, Inc. Stent having time-release indicator
AU2007351374B2 (en) 2006-11-06 2012-11-08 Medtronic, Inc. Mesh pouches for implantable medical devices
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
US8911765B2 (en) 2007-03-29 2014-12-16 Tyrx, Inc. Biodegradable, polymer coverings for breast implants
US9491966B2 (en) 2007-05-02 2016-11-15 Tyrx, Inc. Dihydroxybenzoate polymers and uses thereof
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8652525B2 (en) 2008-07-10 2014-02-18 Tyrx, Inc. NSAID delivery from polyarylates
JP5671463B2 (en) 2008-09-22 2015-02-18 タイレックス・インコーポレイテッドＴｙｒｘ Ｉｎｃ． Linear polyester amides from aminophenol esters
JP5847706B2 (en) * 2009-06-01 2016-01-27 タイレックス・インコーポレイテッドＴｙｒｘ Ｉｎｃ． Compositions and methods for preventing sternum wound infections
US9839628B2 (en) 2009-06-01 2017-12-12 Tyrx, Inc. Compositions and methods for preventing sternal wound infections
JP5944314B2 (en) * 2009-07-31 2016-07-05 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー Biocompatible polymers for medical devices
US8409279B2 (en) 2009-10-01 2013-04-02 Lipose Corporation Breast implant implantation method and apparatus
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP2609162B1 (en) 2010-08-25 2018-12-12 Tyrx, Inc. Novel medical device coatings
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6397190B2 (en) 2010-11-12 2018-09-26 タイレックス・インコーポレイテッドＴｙｒｘ Ｉｎｃ． Fixing device containing active pharmaceutical ingredients
AU2012283875B2 (en) 2011-07-20 2016-05-12 Medtronic, Inc. Drug eluting mesh to prevent infection of indwelling transdermal devices
WO2014018748A1 (en) 2012-07-25 2014-01-30 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014137454A1 (en) 2013-03-07 2014-09-12 Tyrx, Inc. Methods and compositions to inhibit the assemblage of microbial cells irreversibly associated with surfaces of medical devices
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
CN106061494A (en) 2013-10-10 2016-10-26 辛纳吉制药公司 Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
CN105431178A (en) 2013-11-08 2016-03-23 泰尔克斯公司 Antimicrobial compositions and methods for preventing surgical incision site infection
EP3177319A1 (en) * 2014-08-04 2017-06-14 Janssen Sciences Ireland UC Compacted solid dosage form
CA3009814A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
WO1997019996A1 (en) * 1995-11-27 1997-06-05 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
WO1998036013A1 (en) * 1997-02-18 1998-08-20 Rutgers, The State University Monomers derived from hydroxy acids and polymers prepared therefrom
WO1999024107A1 (en) * 1997-11-07 1999-05-20 Rutgers, The State University Biodegradable, anionic polymers derived from the amino acid l-tyrosine
WO1999029758A1 (en) * 1997-12-12 1999-06-17 Samyang Corporation Positively-charged poly[alpha-(omega-aminoalkyl)glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake
WO1999052962A1 (en) * 1998-04-13 1999-10-21 Rutgers, The State University The construction of copolymer libraries

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719817A1 (en) * 1997-05-13 1998-11-19 Hoechst Ag Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids
KR100686784B1 (en) * 1999-02-05 2007-02-23 알리엔 테크놀로지 코포레이션 Apparatuses and methods for forming assemblies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
WO1997019996A1 (en) * 1995-11-27 1997-06-05 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
WO1998036013A1 (en) * 1997-02-18 1998-08-20 Rutgers, The State University Monomers derived from hydroxy acids and polymers prepared therefrom
WO1999024107A1 (en) * 1997-11-07 1999-05-20 Rutgers, The State University Biodegradable, anionic polymers derived from the amino acid l-tyrosine
WO1999029758A1 (en) * 1997-12-12 1999-06-17 Samyang Corporation Positively-charged poly[alpha-(omega-aminoalkyl)glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake
WO1999052962A1 (en) * 1998-04-13 1999-10-21 Rutgers, The State University The construction of copolymer libraries

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHA Y ET AL: "a one-week subdermal delivery system for l-methadone based on biodegradable microcapsules", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 7, no. 1, April 1988 (1988-04-01), pages 69 - 78, XP002143620, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
AU784226B2 (en) 2006-02-23
WO2001049249A3 (en) 2002-01-17
AU2925501A (en) 2001-07-16
CA2396037A1 (en) 2001-07-12
JP2003519164A (en) 2003-06-17
WO2001049249A2 (en) 2001-07-12
EP1263453A2 (en) 2002-12-11

Similar Documents

Publication Publication Date Title
EP1263453A4 (en) PHARMACEUTICAL FORMULATION CONSISTING OF A POLYMERMATRIX, FOR REGULATING THE TIME-CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES
EP1251864A4 (en) PHARMACEUTICAL FORMULATION CONSISTING OF A POLYMER MIXTURE AND AN ACTIVE CONNECTION FOR TIME-CONTROLLED RELEASE
DE69830095D1 (en) Pharmaceutical, cosmetic or dermo-pharmaceutical patch for the administration of several different active substances
EE200100714A (en) Spraying systems and methods for pharmaceutical formulations
ATE228823T1 (en) PHARMACEUTICAL AEROSOL FORMULATION
AT400295B (en) ORAL SOLID PHARMACEUTICAL DOSAGE FORM WITH PROGRAMMED ACTIVE SUBSTANCE RELEASE AND METHOD FOR THE PRODUCTION THEREOF
ATE274902T1 (en) PHARMACEUTICAL DOSAGE FORMS FOR CONTROLLED PULSATE DELIVERY
DE69812089D1 (en) PHARMACEUTICAL OMEPRAZOLE FORMULATION
GB2402063B (en) Pharmaceutical composition for controlled release of active substances and the manufacturing method thereof
ATE233263T1 (en) HETEROCYCLIC COMPOUNDS FOR INHIBITING STOMACHIC ACID PRODUCTION, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS THEREOF
DK1242055T3 (en) Hydrogel controlled dosage form for drugs
ATE252562T1 (en) PYRAZOLECARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
ATE516812T1 (en) PHARMACEUTICAL FORMULATIONS FOR SUSTAINED DRUG RELEASE
ATE317688T1 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING A BENZIMIDAZOLE DERIVATIVE WITH ANTIULCULAR ACTION AND METHOD FOR THE PRODUCTION THEREOF
ATE331529T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ANTIGEN
DE60118859D1 (en) Pharmaceutical composition containing trehalose for ophthalmic use
EE03904B1 (en) Granule, pharmaceutical dosage form, method of preparation of the granules and drug-coated granules
EE200000383A (en) Oral pharmaceutical extended release dosage form
FIU20000164U0 (en) New pharmaceutical formulation
DE60131760D1 (en) DEVICE FOR THE ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE ACTIVE IN POWDER FORM
DE60232147D1 (en) PHARMACEUTICAL PREPARATION WITH DELAYED ACTIVE RELEASE CONTAINING MILKYLIC ACID GLYCOLIC ACID COPOLYMER, AND METHOD FOR THE PRODUCTION THEREOF
IL156262A0 (en) Anti-cd28 antibodies having no mitogenic activity and pharmaceutical compositions containing the same
ATE383868T1 (en) PHARMACEUTICAL FORMULATION CONTAINING MEGALATRAN AND ITS PROPHARMACEUTICALS
NO20001375L (en) Drug formulation with controlled release
ATE247981T1 (en) PHARMACEUTICAL PREPARATION CONTAINING PROTEIN

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020723

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

R17P Request for examination filed (corrected)

Effective date: 20020723

A4 Supplementary search report drawn up and despatched

Effective date: 20080121

17Q First examination report despatched

Effective date: 20080718

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110207